a All regimens may also be used for pericardial mesothelioma and tunica vaginalis testis mesothelioma.
b Broad molecular tumor profiling is recommended with the goal of identifying rare driver alterations (eg, NTRK or ALK) for which effective drugs may be available or to
appropriately counsel patients regarding the availability of clinical trials.25
c An FDA-approved biosimilar is an appropriate substitute for bevacizumab.
d Pembrolizumab and berahyaluronidase alfa-pmph subcutaneous injection may be substituted for IV pembrolizumab. Pembrolizumab and berahyaluronidase alfa-pmph has
different dosing and administration instructions compared to IV pembrolizumab.
e Consider rechallenge with pemetrexed-based therapy, if good response to front-line pemetrexed-based treatment.26
f Nivolumab and hyaluronidase-nvhy is not approved for concurrent use with IV ipilimumab; however, for nivolumab monotherapy, nivolumab and hyaluronidase-nvhy
subcutaneous injection may be substituted for IV nivolumab. Nivolumab and hyaluronidase-nvhy has different dosing and administration instructions compared to IV nivolumab. NCCN恶性胸膜间皮瘤指南导航
